ArticleAdvances in virology2025
The Genetic Diversity and Drug Resistance Patterns of HIV-1 Pol Gene in East Africa.
Article in Advances in virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HIV treatment failure in tertiary care: clinical epidemiology and preliminary mechanistic characterisation.Frontiers in public health · 2026Article
- The Genetic Diversity and Drug Resistance Patterns of HIV-1 Pol Gene in East Africa.Advances in virology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human immunodeficiency virus-1 (HIV-1) is among the most genetically diverse pathogens due to expeditious molecular evolution. The rapid change in HIV genomes intricates HIV transmission and progression and attributes HIV resistance to antiretroviral therapy (ART). In East Africa, as in other parts of the globe, HIV-1 occurs in various subtypes, circulating recombinant form (CRF) and unique recombinant forms, with subtype A1 being the most predominant. Surveillance of HIV-1 molecular diversity and drug resistance mutations (DRMs) is a linchpin for monitoring viral evolution and treatment efficiency. However, consolidated reports on the same are limited, and therefore, the pursuit of meta-analysis was sought to analyze genetic diversity and drug resistance patterns of HIV-1 pol gene and their geographical distributions in four East African countries (Kenya, Uganda, Tanzania, and Ethiopia). We retrieved 7614 HIV-1 pol gene sequences, deposited between 2015 and 2025 from the Los Alamos HIV databases. The predominant HIV-1 subtypes were A1 (40.2%), C (21.5%), and D (17.7%), with geographical variability. A notable frequency of inter-subtype recombinant was observed with recombinants A1D (9.5%) and A1C (2.94%) being prevalent. Few CRFs (> 0.1%) were identified. DRM were present in 42.8% of the sequences, with the majority associated with NNRTIs (36.5%) and NRTIs (25.5%). The most frequently associated mutations were K103N and M184V. Although resistance to INSTI (3.7%) remained minimal, its presence warrants continued monitoring. A significant association between HIV-1 subtypes and DRM prevalence was observed (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.